Back to search
FDAFDA · Food and drugs·Recall number D-0209-2015

PAPAV HCL/PHENTOL/PROSTAGL, 12mg/1mg/10mcg, injectable, 1.25 mL glass vial or 1.7 ml glass vial, RX, Creative Compounds, Wilsonville, OR 97070

Published November 12, 2014 · Recall initiated: October 6, 2014

Summary

FDA records drug Class II recall D-0209-2015, published November 12, 2014 and initiated October 6, 2014. Recalling firm: Oregon Compounding Centers, Inc. dba Creative Compounds; Status: Terminated; Reported quantity: 25 mL; Lot: Lot #: 20140827@30, discard date: 10/11/2014; Lot #: 20140910@28/1.7, discard date: 10/25/2014; Lot #: 20140917@2/1.25, discard date: 11/1/2014. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Oregon Compounding Centers, Inc. dba Creative Compounds
Distributor
Oregon, Washington
Lot
Lot #: 20140827@30, discard date: 10/11/2014; Lot #: 20140910@28/1.7, discard date: 10/25/2014; Lot #: 20140917@2/1.25, discard date: 11/1/2014.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was PAPAV HCL/PHENTOL/PROSTAGL, 12mg/1mg/10mcg, injectable, 1.25 mL glass vial or 1.7 ml glass vial, RX, Creative Compounds, Wilsonville, OR 97070 recalled?

Yes. FDA published recall D-0209-2015 on November 12, 2014. Reported hazard: Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release